Risk factors for infections and secondary malignancies in patients with a myeloproliferative neoplasm treated with ruxolitinib: a dual-center, propensity score-matched analysis.
JAK inhibitor
Ruxolitinib
infection
myeloproliferative
Journal
Leukemia & lymphoma
ISSN: 1029-2403
Titre abrégé: Leuk Lymphoma
Pays: United States
ID NLM: 9007422
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
pubmed:
13
11
2019
medline:
29
4
2021
entrez:
13
11
2019
Statut:
ppublish
Résumé
Ruxolitinib is a JAK1/2 inhibitor approved for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Recent data have suggested the possibility of increased infectious and secondary malignancy rates in patients treated with ruxolitinib. We conducted a dual-center, retrospective study of 202 myeloproliferative neoplasm (MPN) patients receiving ruxolitinib and a control cohort of 73 ruxolitinib-naïve MPN patients. We utilized propensity score matching to analyze the primary outcome of development of any grade infection. Infections occurred in 38.4% of ruxolitinib-naïve patients and 42.6% of ruxolitinib-treated patients and were primarily grade 1/2. After propensity score weighting, there was no difference in risk of infection between ruxolitinib-treated and -naïve patients with MF (HR 1.15 [95% CI 0.80-1.65],
Identifiants
pubmed: 31711337
doi: 10.1080/10428194.2019.1688323
pmc: PMC7771191
mid: NIHMS1656437
doi:
Substances chimiques
Nitriles
0
Pyrazoles
0
Pyrimidines
0
ruxolitinib
82S8X8XX8H
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
660-667Subventions
Organisme : NCI NIH HHS
ID : P01 CA108671
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL053762
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Ann Hematol. 2018 May;97(5):913-914
pubmed: 29340760
N Engl J Med. 2012 Mar 1;366(9):787-98
pubmed: 22375970
Ann Hematol. 2017 Mar;96(3):387-391
pubmed: 27889820
Hematology. 2016 Jan;21(1):3-9
pubmed: 26214121
Haematologica. 2016 Sep;101(9):1065-73
pubmed: 27247324
Am J Hematol. 2018 Mar;93(3):339-347
pubmed: 29150886
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Ann Hematol. 2016 Jan;95(2):361-2
pubmed: 26486358
Blood. 2019 May 23;133(21):2348-2351
pubmed: 30796023
Blood. 2018 Aug 16;132(7):694-706
pubmed: 29907599
Leuk Res. 2015 Aug 12;:
pubmed: 26364797
Am J Hematol. 2017 Jan;92(1):37-41
pubmed: 27701770
Int J Hematol. 2017 Mar;105(3):309-317
pubmed: 27832516
J Clin Oncol. 2015 Jul 10;33(20):2288-95
pubmed: 26033810
Ann Hematol. 2016 Jun;95(7):1207-9
pubmed: 27113251
Blood. 2013 Nov 28;122(23):3843-4
pubmed: 24288410
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Leukemia. 2016 Aug;30(8):1701-7
pubmed: 27211272
Blood. 2013 Aug 15;122(7):1192-202
pubmed: 23770777
N Engl J Med. 2015 Jan 29;372(5):426-35
pubmed: 25629741